# Elucid

> Elucid is a Boston medical technology company providing cloud-based analysis of CT angiography to quantify and characterize coronary and carotid plaque. Its Plaque-IQ software uses algorithms trained and validated against histology, with clinician-facing reports and lesion inspection tools to support cardiovascular assessment.

- **Founded:** 2013
- **Headquarters:** Boston, United States
- **Founders:** Andrew Buckler (Founder; former President and CTO), Marc Manley (Co-founder (reported by Preqin))
- **Products:** Plaque-IQ (PlaqueIQ), Carotid PlaqueIQ, Lesion Inspection Tool, BioIntegrated FFR-CT, ElucidVivo / vascuCAP
- **Notable:** PlaqueIQ received FDA 510(k) clearance September 12, 2024 (K241524); company announcement followed October 1., Commercial carotid plaque analysis launched October 2025., Lesion Inspection Tool commercially available April 2026.

## Products & services

- **Plaque-IQ (PlaqueIQ)** — FDA-cleared cloud image analysis of previously acquired CT angiography, quantifying plaque amount and morphology with histology-trained algorithms and analyst-generated segmentation.
- **Carotid PlaqueIQ** — Plaque morphology quantification and classification for carotid arteries; commercial launch announced October 29, 2025.
- **Lesion Inspection Tool** — Lets physicians interrogate selected lesions or regions and examine segment-specific composition and burden within Plaque-IQ.
- **BioIntegrated FFR-CT** — Investigational plaque-derived assessment of coronary physiology; 510(k) submission under FDA review in September 2026.
- **ElucidVivo / vascuCAP** — Earlier product and research software names appearing in published plaque characterization studies and prior regulatory documentation.

## Achievements

- PlaqueIQ received FDA 510(k) clearance September 12, 2024 (K241524); company announcement followed October 1.
- Commercial carotid plaque analysis launched October 2025.
- Lesion Inspection Tool commercially available April 2026.
- Plaque-IQ received the 2026 MedTech Breakthrough award for Best New Cardiology Technology Solution.
- Approximately $185 million total funding reported in September 2026 Series D announcement.

## Latest updates

- **2026-09** — Appointed Mark Miller chief revenue officer September 29 ahead of a planned BioIntegrated FFR-CT launch subject to FDA clearance.
- **2026-09** — Announced $55 million Series D September 2, reporting approximately $185 million total raised.
- **2026-07** — Announced first AI-PREDICT enrollment July 9; approximately 1,000 subjects and more than 20 sites planned.
- **2026-04** — Announced commercial availability of the Lesion Inspection Tool April 15.

## Links

- Website: https://elucid.com/
- LinkedIn: https://www.linkedin.com/company/elucid-inc/
- Twitter/X: https://twitter.com/ElucidBio
- YouTube: https://www.youtube.com/@elucidbioimaging

---

Profile page: https://yespress.io/elucid
Published by YesPress — https://yespress.io
Last updated: 2026-10-05